|
Akari Therapeutics, Plc (AKTX) DCF Valuation |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Akari Therapeutics, Plc (AKTX) Bundle
Evaluate Akari Therapeutics, Plc's financial prospects like an expert! This (AKTX) DCF Calculator provides pre-filled financial data and the complete flexibility to modify revenue growth, WACC, margins, and other critical assumptions to align with your predictions.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -24.7 | -20.4 | -17.2 | -23.1 | -16.8 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -24.8 | -20.5 | -17.2 | -23.1 | -16.8 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 5.7 | 14.1 | 9.4 | 13.2 | 3.8 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | -1.0 | -.5 | .0 | -2.5 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | 1.2 | 3.4 | 1.8 | .9 | 1.7 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -21.8 | -17.6 | -17.4 | -9.1 | -16.8 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -19.5 | -15.9 | -19.5 | -7.4 | -18.6 | -1.7 | .0 | .0 | .0 | .0 |
| WACC, % | 6.89 | 6.89 | 6.89 | 6.89 | 6.89 | 6.89 | 6.89 | 6.89 | 6.89 | 6.89 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -2 | |||||||||
| Net Debt | -4 | |||||||||
| Equity Value | 2 | |||||||||
| Diluted Shares Outstanding, MM | 9,789 | |||||||||
| Equity Value Per Share | 0.00 |
What You Will Get
- Real Akari Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Akari Therapeutics, Plc (AKTX).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates specific to Akari Therapeutics.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Akari’s fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections for Akari Therapeutics.
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility for Akari Therapeutics, Plc (AKTX).
Key Features
- Comprehensive DCF Calculator: Offers detailed unlevered and levered DCF valuation models tailored for Akari Therapeutics, Plc (AKTX).
- WACC Calculator: Features a pre-built Weighted Average Cost of Capital sheet with adjustable inputs specific to the biotech sector.
- Customizable Forecast Assumptions: Easily adjust growth projections, capital expenditures, and discount rates relevant to Akari Therapeutics, Plc (AKTX).
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios pertinent to Akari Therapeutics, Plc (AKTX).
- Interactive Dashboard and Charts: Visual representations provide a summary of essential valuation metrics for straightforward analysis.
How It Works
- Step 1: Download the prebuilt Excel template featuring Akari Therapeutics’ data.
- Step 2: Navigate through the pre-filled sheets to grasp the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly see the recalculated results, including Akari Therapeutics’ intrinsic value.
- Step 5: Make informed investment decisions or create reports based on the outputs.
Why Choose This Calculator for Akari Therapeutics, Plc (AKTX)?
- Accurate Data: Up-to-date Akari financials provide trustworthy valuation outcomes.
- Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Built-in calculations save you from starting from the ground up.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants in the biotech sector.
- User-Friendly: Simple design and clear instructions ensure accessibility for all users.
Who Should Use This Product?
- Individual Investors: Gain insights to make informed decisions regarding investments in Akari Therapeutics (AKTX).
- Financial Analysts: Enhance analysis efficiency with comprehensive financial models tailored for Akari Therapeutics (AKTX).
- Consultants: Provide clients with accurate and timely valuation assessments of Akari Therapeutics (AKTX).
- Business Owners: Learn from the valuation strategies of biotech companies like Akari Therapeutics (AKTX) to inform your own business plans.
- Finance Students: Explore real-world valuation methodologies using data from Akari Therapeutics (AKTX).
What the Template Contains
- Historical Data: Includes Akari Therapeutics' past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Akari Therapeutics' intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Akari Therapeutics' financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.